By Dan Prochilo ( May 2, 2013, 3:06 PM EDT) -- The Federal Circuit ruled Wednesday that only one of the four patents for Allergan Inc.'s glaucoma drug Combigan was invalid, partly reversing a lower court's decision but still preventing Sandoz Inc. and other generic-drug makers from selling their versions of the drug until after the last of the patents expires in 2022....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.